Literature DB >> 16110800

The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence.

K V Clemons1, D A Stevens.   

Abstract

Animal models of aspergillosis have been used extensively to study various aspects of pathogenesis, innate and acquired host-response, disease transmission and therapy. Several different animal models of aspergillosis have been developed. Because aspergillosis is an important pulmonary disease in birds, avian models have been used successfully to study preventative vaccines. Studies done to emulate human disease have relied on models using common laboratory animal species. Guinea pig models have primarily been used in therapy studies of invasive pulmonary aspergillosis (IPA). Rabbits have been used to study IPA and systemic disease, as well as fungal keratitis. Rodent, particularly mouse, models of aspergillosis predominate as the choice for most investigators. The availability of genetically defined strains of mice, immunological reagents, cost and ease of handling are factors. Both normal and immunosuppressed animals are used routinely. These models have been used to determine efficacy of experimental therapeutics, comparative virulence of different isolates of Aspergillus, genes involved in virulence, and susceptibility to infection with Aspergillus. Mice with genetic immunological deficiency and cytokine gene-specific knockout mice facilitate studies of the roles cells, and cytokines and chemokines, play in host-resistance to Aspergillus. Overall, these models have been critical to the advancement of therapy, and our current understanding of pathogenesis and host-resistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16110800     DOI: 10.1080/13693780500051919

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  29 in total

1.  Drosophila melanogaster as a model to study virulence and azole treatment of the emerging pathogen Candida auris.

Authors:  Sebastian Wurster; Ashwini Bandi; Nicholas D Beyda; Nathaniel D Albert; Nitya M Raman; Isaam I Raad; Dimitrios P Kontoyiannis
Journal:  J Antimicrob Chemother       Date:  2019-07-01       Impact factor: 5.790

Review 2.  Host immune defense against Aspergillus fumigatus: insight from experimental systemic (disseminated) infection.

Authors:  I Mirkov; S Stosic-Grujicic; M Kataranovski
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

3.  Embryonated eggs as an alternative infection model to investigate Aspergillus fumigatus virulence.

Authors:  Ilse D Jacobsen; Katharina Grosse; Silvia Slesiona; Bernhard Hube; Angela Berndt; Matthias Brock
Journal:  Infect Immun       Date:  2010-04-26       Impact factor: 3.441

4.  RNA-Seq Profile Reveals Th-1 and Th-17-Type of Immune Responses in Mice Infected Systemically with Aspergillus fumigatus.

Authors:  Jata Shankar; Gustavo C Cerqueira; Jennifer R Wortman; Karl V Clemons; David A Stevens
Journal:  Mycopathologia       Date:  2018-03-02       Impact factor: 2.574

5.  CD4+ T cells mediate the protective effect of the recombinant Asp f3-based anti-aspergillosis vaccine.

Authors:  Diana Diaz-Arevalo; Karine Bagramyan; Teresa B Hong; James I Ito; Markus Kalkum
Journal:  Infect Immun       Date:  2011-03-21       Impact factor: 3.441

Review 6.  Animal Models of Aspergillosis.

Authors:  Guillaume Desoubeaux; Carolyn Cray
Journal:  Comp Med       Date:  2018-04-02       Impact factor: 0.982

7.  Hypothermic endpoint for an intranasal invasive pulmonary aspergillosis mouse model.

Authors:  Trinka W Adamson; Diana Diaz-Arevalo; Tracey M Gonzalez; Xueli Liu; Markus Kalkum
Journal:  Comp Med       Date:  2013       Impact factor: 0.982

8.  Experimental evidence that granulocyte transfusions are efficacious in treatment of neutropenic hosts with pulmonary aspergillosis.

Authors:  Marife Martinez; Vicky Chen; Ann-Jay Tong; Kelsey Hamilton; Karl V Clemons; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

9.  Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture.

Authors:  Ana C Vallor; William R Kirkpatrick; Laura K Najvar; Rosie Bocanegra; Marsha C Kinney; Annette W Fothergill; Monica L Herrera; Brian L Wickes; John R Graybill; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

10.  A fungal pH-responsive signaling pathway regulating Aspergillus adaptation and invasion into the cornea.

Authors:  Xia Hua; Xiaoyong Yuan; Kirk R Wilhelmus
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-22       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.